

EVEON is accelerating its development for the benefit of pharmaceutical laboratories and patient treatment adherence.

Grenoble, March 8, 2022 – EVEON, designer and manufacturer of medical devices for the preparation and administration of drugs, made numerous project achievements in 2021 in collaboration with pharmaceutical companies. It looks like another promising year ahead for the company as it is carried forward by its dynamism and its innovations for better therapeutic compliance.

EVEON is a leading player in ensuring that new therapies (reconstitutable lyophilisates, dispersible powders, suspensions, dilutions, emulsions, therapy combinations, high viscosity formulations, radiopharmaceuticals, etc.), which all entail a complex preparation or administration process, are easily accessible and available in large quantities.

Over the course of 2021, EVEON made significant developments and broadened its range, which is spread across three large families: **Intuity® Mix** for standardising preparation, **Intuity® Ject** for automated administration, and **Intuity® Spray** for controlled administration of mists/sprays. Each family is made up of various solutions that are tailored to the formulations, primary containers (syringes or cartridges), preparation requirements such as soft mixtures, and administration of everything from microdoses to multidoses.

In addition, EVEON **received the Pharmapack award¹ in October 2021** for its **Intuity® Spray** device, which enables controlled administration of a mist of fine droplets. The patented spray nozzle, a high-tech component of this device, can also be connected to a syringe using a luer for manual administration. This innovation meets the strongly increasing demand for this spray mode of administration, which allowed EVEON to break into new strategic areas of activity in the fourth quarter of 2021.



“EVEON’s teams have successfully developed and created a range of Intuity® platforms to match the evolutions in medical needs. All of the parameters such as the dilution, the injection rate or the process time, and the injected dose, have been automated to give patients and medical personnel very precise, standardised, and if needed, reproducible, preparation and delivery. 2021 was a year of new developments and access to new markets, and we are enthusiastic about the outlook for 2022,” stated Vincent TEMPELAERE, CEO of EVEON.

About EVEON

EVEON is an ISO 13485-certified company that designs and manufactures safe, connected automatic medical devices for the preparation and delivery of therapeutic treatments to improve patient quality of life. EVEON places the needs of patients and care professionals at the heart of its development by designing simple, intuitive devices to improve therapeutic performance, compliance, and the conditions of at-home care.

The company’s expertise has been recognized by Forbes magazines, which ranked EVEON as the 3rd most inventive company in France in the category of medical technology in 2019.

Press contact: Charlotte Reverand | cre@eveon.eu | [@EVEON_SAS](https://twitter.com/EVEON_SAS)
www.eveon.eu

¹ Press release published 12th October 2021 <https://www.eveon.eu/en/news-only/186-pharmapack-award-2021>